Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma - Takeaways - MDSpire

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

  • By

  • Iskander Musabaev

  • Sergey Goryaynov

  • Tatiana Yu Kochetova

  • Valerii Krylov

  • Sergey Ivanov

  • May 29, 2026

  • 0 min

Share

  • 1

    Prostate cancer is the most commonly diagnosed cancer in men globally, while meningioma is a prevalent primary CNS tumor.

  • 2

    The patient received four administrations of [225Ac]Ac-PSMA-617 after PET/CT showed high uptake in both metastatic prostate cancer and meningioma.

  • 3

    Post-treatment, the patient exhibited a 99.8% decrease in PSA levels and a 90.6% reduction in meningioma size, with stable hematological parameters.

  • 4

    High-grade xerostomia was noted as an unfavorable symptom following treatment, indicating potential side effects of the therapy.

  • 5

    This case expands the understanding of PSMA RLT as a treatment for both prostatic and non-prostatic tumors, including meningiomas.

Original Source(s)

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

  • by Iskander Musabaev, Sergey Goryaynov, Tatiana Yu Kochetova, Valerii Krylov, Sergey Ivanov

  • May 29, 2026

Related Content

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer